Elliot Ehrich, MD
About Elliot Ehrich, MD
Elliot Ehrich is the CMO and EVP of Translational Science with over 25 years of experience in pharma and biotech, having contributed to the development and registration of 8 medicines across various therapeutic areas.
Title: CMO and EVP, Translational Science
Elliot Ehrich serves as the Chief Medical Officer (CMO) and Executive Vice President (EVP) of Translational Science. In his role, he focuses on translating scientific discoveries into novel treatments for conditions that lack effective therapies. He has directed his career towards bridging the gap between groundbreaking research and practical medicine, aiming to address unmet medical needs.
Professional Background and Experience
Elliot Ehrich has amassed over 25 years of experience in the pharmaceutical and biotech industries. He has played key roles in the discovery, development, and successful registration of eight medicines covering a wide range of therapeutic areas. His career highlights include leadership positions at Alkermes, Inc. and Skyhawk Therapeutics. At Alkermes, he was pivotal in transforming the R&D focus toward novel small molecule therapeutics. At Skyhawk Therapeutics, he oversaw research, drug discovery, and development activities as the President.
Previous Roles and Contributions
Prior to joining LifeMine, Elliot Ehrich was a Venture Partner at 5AM Ventures, where he contributed to early-stage life science companies. His industry career began at Merck Research Labs in the clinical pharmacology group, where he gained extensive experience in human pharmacokinetics and drug-exposure-response relationships. During his time at Merck, he also worked in pulmonary-immunology clinical development. At Alkermes, he led efforts that resulted in FDA registrations for medications treating schizophrenia, alcohol and opioid dependence, and multiple sclerosis, and initiated a novel cytokine program for cancer treatment.
Education and Medical Training
Elliot Ehrich completed his undergraduate studies with a B.A. in Biochemistry from Princeton University. He furthered his education as a predoctoral fellow in molecular genetics at the European Molecular Biology Laboratory in Heidelberg, Germany. He earned his M.D. from Columbia University. Post-graduation, he underwent an extensive medical training regimen, including an internship and residency in internal medicine, as well as a clinical fellowship in immunology and rheumatology, all at Stanford University. Additionally, he completed a Cancer Research Institute-sponsored postdoctoral fellowship in T cell biology.
Achievements in Drug Development
Throughout his career, Elliot Ehrich has led or contributed to the development of several significant pharmaceutical initiatives. At Alkermes, he spearheaded the registration of medications for various conditions, including schizophrenia, alcohol and opioid dependence, and multiple sclerosis. His work also includes the initiation of a novel cytokine program for the treatment of malignancies, which is currently undergoing phase 3 clinical development. These contributions are testament to his commitment to addressing unmet medical needs through innovative drug development.